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Outer Membrane Protein (MOMP) epitopes. Besides the defined serovar, genovariants have 66 been described including Ja and L2b (7, 8) . 67 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   3   69 The majority of serovars A, B and C are detected in conjunctival samples of patients in 70 developing countries, while serovars D-K are mostly found in the urogenital tract and 71 proctum and remain confined to the mucosal layer. The serovars L1, L2 and L3 in contrast 72 invade the submucosal connective tissue layers and disseminate to locoregional lymph nodes 73 causing lymphogranuloma venereum (LGV). In the developed countries, LGV Ct serovars are 74 mostly detected in HIV-positive men who have sex with men (MSM). Because LGV Ct 75 infections require longer antibiotic treatment, it is highly recommended to differentiate them 76 from non-LGV serovars (9) . 77 A number of reverse line blot assays were developed making genotyping faster and less 78 laborious, compared to sequencing (10) (11) (12) . The Ct-Detection genoTyping (DT) assay 79 consists of a Ct amplification step (PCR), a Ct Detection step (DNA Enzyme Immuno Assay; 80 DEIA) and a Ct genotyping step (Reverse Hybridization Assay; RHA). This assay is an 81 alternative for Omp1 sequencing by differentiating between the 14 major serovars (12, 13) . 82
Besides genotyping of the Omp1 gene, a new real time PCR based on the pmpH gene (pmpH 83 PCR) can differentiate between an LGV Ct infection and a non-LGV Ct infection (13 The DNA isolates were amplified by a nested Omp1 PCR, using a C1000 PCR machine (Bio-110
Rad, Veenendaal, the Netherlands). The outer PCR was performed in a volume of 25 μl, 111 containing 2 μl of isolated DNA, 0.63 U GoTaq polymerase (Promega, Leiden, the 112 Netherlands), 2mM MgCl 2 , 25 μM of each dNTP, 0.11 μM of the primer ompA OF (Table 1) 
Ct-DT amplification, detection and genotyping 127
The Ct amplification (Broad spectrum-Multiplex-PCR), DEIA and RHA of the Ct-DT assay 128
were performed according to the manufacturer's instructions (Labo Biomedical Products BV, 129
Rijswijk, The Netherlands) and as described previously (12, 14) . Briefly, amplification was 130 performed with the Ct-DT-PCR, followed by Ct detection with the Ct-DT-DEIA. All Ct 131 positive samples were further genotyped with the Ct-DT-RHA. 132
Ct-DT-PCR: A 10 μl aliquot of extracted DNA was used for each PCR reaction. The Ct PCR 133 primer set was used to amplify all known serovars available in GenBank. Briefly, this 134 multiplex primer set amplifies a small fragment of 89 base pairs from the endogenous plasmid 135 and a fragment of 160/157 base pairs from the Variable Region 2 of the Omp1 gene. The1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
Omp1 sequencing 171
Fourteen of the 50 samples were Omp1 negative by the nested PCR and could not be 172 sequenced. From 36 samples the complete Omp1 gene was sequenced and analyzed (Table 2) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 Discussion 212
The aim of this study was to evaluate the sensitivity and discriminatory power of three 213 different genotyping methods. In this study, we showed that the Ct-DT-RHA is a rapid and 214 simple alternative for Omp1 sequencing and is suitable for different clinical materials (first 215 void urine, rectal swabs and urogenital swabs). The Ct-DT-RHA has the possibility to detect 216 multiple serovars in clinical samples. Multiple infections will cause sequencing difficulties 217 leading to a non interpretable Omp1 sequence. In other studies 4-12% of the Ct infections 218 contained multiple serovars (11, 16) , making the Ct-DT-RHA more suitable for serovar 219 distribution studies and future Ct vaccine studies compared to Omp1 sequencing. All LGV 220 strains detected by Omp1 sequencing and the pmpH PCR were recognized by the Ct-DT-221 RHA, indicating that the Ct-DT assay can also be used for LGV serovar detection. 222
The Ct positive samples were selected based on the AC2 test results. The AC2 test platform is 223 considered the most sensitive RNA detection system (17) . Eight samples were negative with 224 all three genotyping methods possibly caused by a low Ct DNA load. The 8 samples were 225 analyzed with another Ct detection method (COBAS TaqMan, Roche Molecular Systems, 226
Branchburg, NJ). Seven samples were also negative with the COBAS TaqMan, implicating 227 degradation of DNA due to storage, false positivity of AC2 test or an increased sensitivity of 228 the AC2 test. The 2 Ct endogenous plasmid positive samples that could not be genotyped 229
were also examples of a low DNA load (18, 19) . 230
While the Ct-DT-RHA is a rapid alternative in serovar distribution studies, the Ct Omp1 231 sequencing system has a higher discriminating power, because Ct Omp1 sequencing 232 recognised most point mutations that were missed with the Ct-DT-RHA. This makes Omp1 233 sequencing more useful in networking studies and phylogenetical Ct studies. 234
The pmpH PCR detected all six LGV strains found with Omp1 sequencing. Nevertheless, the 235 pmpH PCR has a low sensitivity for Ct typing of urogenital Ct strains compared with the Ct-236 DT-RHA and Omp1 sequencing. The low sensitivity may be the result of a less sensitive non-237
LGV PCR, sequence differences in the probe and or primer region relative to the circulating 238 patient strains, a low bacterial load, and a 10-fold lower input in the PCR relative to the AC2 239 test. Because the highly sensitive AC2 test is used as first Ct detection method (before 240 performance of the pmpH PCR) and the pmpH PCR detected all LGV variants, this algorithm 241 can be used for differentiating between a urogenital Ct strain and a LGV Ct strain. 242
The LGV serovar samples were found in a population (MSM) that has a very high risk profile 243 for other STI's and multiple Ct infections that might be missed by Omp1 sequencing and the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   9   6 LGV positive samples with the Ct-DT-RHA. Other studies, containing larger sample 246 numbers of anal Ct infections in MSM, are needed to investigate the prevalence of multiple 247 infections among LGV positive MSM. 248
In conclusion, the Ct-DT-RHA is the most sensitive genotyping method, compared with 249
Omp1 sequencing and the pmpH PCR, making the Ct-DT-RHA appropriate for serovar 250 distribution studies, but also for differentiating between a LGV and Non-LGV infections. 251
Omp1 sequencing will determine additional information about point mutations in the Omp1 252 gene, while a multiple Ct infections can lead to a non interpretable sequence result. The new 253
pmpH PCR is suitable as second assay to detect LGV infections, but not as primary detection 254 assay, due to its low sensitivity for non-LGV strains. 255
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